Skip to main content
. 2015 Oct 5;128(19):2557–2564. doi: 10.4103/0366-6999.166026

Table 5.

Adverse events reported during the study, n (%)

Items Wenxin Keli group (n = 600) Placebo group (n = 600)
Abdominal discomfort 0 1 (0.2)
Gastrointestinal symptoms 1 (0.2) 1 (0.2)
Headache 1 (0.2) 0
Dizziness 1 (0.2) 0
Palpitation 0 1 (0.2)
Osphyalgia 0 1 (0.2)
Total adverse events 3 (0.5) 4 (0.7)
Withdrew due to Wenxin Keli 0 1 (0.2)